Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Cardiothorac Surg. 2018 Sep 1;54(3):460-466. doi: 10.1093/ejcts/ezy064.

An early European experience with transapical off-pump mitral valve repair with NeoChord implantation.

Author information

1
Cardiac Surgery Unit, Department of Cardiac, Thoracic, and Vascular Sciences, University of Padua, Padua, Italy.
2
Department of Cardiovascular Medicine, Vilnius University, Vilnius, Lithuania.
3
Department of Thoracic and Cardiovascular Surgery, University Medical Center, Georg-August University, Göttingen, Germany.
4
CardioVascular Center Frankfurt CVC, Sankt Katharinen, Frankfurt, Germany.
5
Division of Cardiac Surgery, Department of Surgical Sciences, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
6
Department of Internal Medicine and Cardiology, Medical University of Warsaw, Warsaw, Poland.
7
Department of Cardiac Surgery, Medicover Hospital, Warsaw, Poland.
8
Department of Cardiovascular Surgery, Sant'Orsola-Malpighi Hospital, Bologna University, Bologna, Italy.

Abstract

OBJECTIVES:

Transapical off-pump NeoChord repair is a novel minimally invasive surgical procedure to treat degenerative mitral valve regurgitation. The aim was to evaluate 1-year clinical results of the NeoChord procedure in a consecutive cohort of patients.

METHODS:

Between February 2013 and July 2016, 213 patients were enrolled in the NeoChord Independent International Registry. All patients presented severe mitral regurgitation due to flail/prolapse of 1 or both leaflets, and they all completed postoperative echocardiographic assessment up to 1 year. We identified the primary end point as composed of procedural success, freedom from mortality, stroke, reintervention, recurrence of severe mitral regurgitation, rehospitalization and decrease of at least 1 New York Heart Association functional class at 1-year follow-up. We also compared outcomes according to the anatomical classification (Type A: isolated central posterior leaflet disease; Type B: posterior multisegment disease; Type C: anterior, bileaflet, paracommissural disease with/without leaflet/annular calcifications).

RESULTS:

The median age was 68 years (interquartile range 56-77), and the median EuroSCORE II was 1.05% (interquartile range 0.67-1.76). The number of Type A, B and C patients was 82 (38.5%), 98 (46%) and 33 (15.5%), respectively. Procedural success was achieved in 206 (96.7%) patients. At 1-year follow-up, overall survival was 98 ± 1%. Composite end point was achieved in 84 ± 2.5% for the overall population and 94 ± 2.6%, 82.6 ± 3.8% and 63.6 ± 8.4% in Type A, Type B and Type C patients, respectively (P < 0.0001).

CONCLUSIONS:

These results demonstrate that the NeoChord procedure is safe, effective and reproducible. Clinical and echocardiographic efficacy is maintained up to 1 year with significant differences among the anatomical groups. Specific anatomical selection criteria are necessary to achieve stable results.

PMID:
29514183
DOI:
10.1093/ejcts/ezy064

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center